Eloxx Pharmaceuticals (ELOX) vs Xilio Therapeutics (XLO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eloxx Pharmaceuticals is the larger company by market cap ($61.3 million vs $59.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELOX | XLO |
|---|---|---|
| Share price | $15.18 | $9.01 |
| Market cap | $61.27M | $59.29M |
| 1-day change | +2.02% | 0.00% |
| YTD return | — | +0.56% |
| 1-year return | — | -23.48% |
| P/E ratio (TTM) | 4.31 | — |
| EPS (TTM) | $3.52 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.40 | $12.59 |
| 52-week low | $8.20 | $6.47 |
| Distance from 52-week high | -35.13% | -28.41% |
| Analyst consensus | none | none |
| Avg. price target upside | +151.98% | +121.98% |
| Average volume | 46.44K | 19.07K |
| Shares outstanding | 4.04M | 6.58M |
| Employees | 10 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Xilio Therapeutics
XLO stock →Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
ELOX vs XLO FAQ
Which is bigger, Eloxx Pharmaceuticals or Xilio Therapeutics?
Eloxx Pharmaceuticals (ELOX) is larger, with a market capitalization of $61.27M compared with $59.29M for Xilio Therapeutics (XLO).
Are Eloxx Pharmaceuticals and Xilio Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Eloxx Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Xilio Therapeutics.